Can I Take Green Tea Extract (EGCG) with Provigil (Modafinil)?

Direct answer

Modafinil (brand name Provigil) is FDA-approved for narcolepsy, obstructive sleep apnea with residual sleepiness despite CPAP, and shift-work sleep disorder. Green tea extract is a concentrated supplement form of green tea leaf standardized to its dominant active compound, EGCG, and frequently containing residual caffeine unless labeled decaffeinated. No controlled human pharmacokinetic trial has measured modafinil blood levels with and without concurrent EGCG supplementation, so the CYP3A4 interaction discussed in laboratory studies remains a theoretical concern in people rather than a confirmed clinical effect. The two risks that do have evidentiary support are additive stimulant and cardiovascular effects from caffeine in most green tea extract products, and a hepatotoxicity signal from concentrated EGCG doses at or above roughly 800 mg per day described in a 2018 EFSA scientific opinion, which exists independent of any interaction with modafinil.

Why this combination raises two different questions

The stimulant layer: caffeine plus modafinil

Modafinil promotes wakefulness through dopamine transporter blockade and effects on hypothalamic histamine release [1]. Caffeine works through a different mechanism, adenosine receptor antagonism, but the downstream effects (alertness, elevated heart rate, suppressed sleep drive) can add up rather than cancel out. A crossover study found that modafinil alone produced measurable increases in subjective alertness compared with placebo [2]; adding caffeine to a stimulant baseline is a well-established way to further raise heart rate and blood pressure.

Green tea extract capsules marketed for weight loss or cognitive support often carry meaningful caffeine content unless the label specifies decaffeinated. Checking the supplement facts panel for total methylxanthine content, and counting it alongside dietary coffee or tea, is the practical step here rather than assuming green tea extract is caffeine-free because it is "natural."

The metabolic layer: a plausible but unconfirmed CYP3A4 overlap

Modafinil is partly metabolized by CYP3A4 and CYP2C19, and it is itself a moderate inducer of CYP3A4 over repeated dosing [3]. Green tea catechins, including EGCG, have shown inhibitory activity against CYP-mediated metabolic pathways in laboratory (in vitro) systems using human liver preparations [4]. Laboratory inhibition of an enzyme does not automatically translate into a meaningful change in a person's drug levels, because oral EGCG has low and variable bioavailability, meaning achievable plasma concentrations from a typical supplement dose may not reach the concentrations tested in these laboratory systems [9].

Modafinil's own CYP3A4 induction complicates this further. Induction builds over roughly one to two weeks of continuous dosing [5], so if EGCG's inhibitory effect is real in vivo, it would be most relevant in the early days of starting both agents together, before modafinil's own induction has had time to develop. This is a mechanistic argument, not a measured clinical finding, and it should be read as a reason for caution rather than a quantified risk.

A separate human pharmacokinetic study found that green tea extract substantially reduced plasma levels of the beta-blocker nadolol, but through inhibition of the OATP1A2 transport protein rather than through CYP enzymes [10]. This shows that green tea extract's drug interaction profile is not limited to CYP3A4, and it illustrates why results from one drug pairing should not be assumed to transfer directly to modafinil, whose transporter-level pharmacokinetics are less well characterized. The exact magnitude reported in that nadolol study should be verified against the primary paper before being cited as a number in clinical counseling.

What is established, what is plausible, and what is not established

Hepatotoxicity: the better-established of the two concerns

The European Food Safety Authority's 2018 scientific opinion on green tea catechins concluded that concentrated EGCG intakes at or above roughly 800 mg per day are associated with a safety signal for liver injury, based on case reports of hepatocellular injury linked to concentrated supplement products rather than brewed tea [6]. This is a supplement-dose concern, separate from whether a person also takes modafinil. Reviews of dietary supplement-associated liver injury cases reported to the U.S. Drug-Induced Liver Injury Network have included green tea extract among the supplements implicated [11]; the exact frequency ranking should be checked against the primary paper before it is cited as a specific statistic.

Modafinil is hepatically metabolized, and post-marketing data include rare reports of liver enzyme elevation, though the FDA label does not list hepatotoxicity as a common adverse effect [7]. Combining a hepatically cleared drug with a supplement that carries its own documented hepatotoxicity signal at high doses is a reasonable basis for caution and monitoring, even without a demonstrated interaction between the two substances.

Dose ranges to think about, not to self-prescribe

These ranges describe how the existing evidence changes in character as EGCG dose rises. They are not individualized dosing advice, and any specific regimen should be reviewed with a prescriber or pharmacist.

Below roughly 400 mg EGCG/day, decaffeinated: the laboratory CYP3A4 inhibition concentrations reported for EGCG are less likely to be reached, and this sits well under the EFSA hepatotoxicity signal threshold. This is generally treated as the lower-risk pattern.

Roughly 400 to 800 mg EGCG/day, or any caffeinated product: this is a gray zone. Baseline liver enzymes and a follow-up check within four to eight weeks of starting or changing the combination is a reasonable precaution, along with attention to blood pressure and resting heart rate if the product is caffeinated.

Above roughly 800 mg EGCG/day: this crosses into the range the EFSA opinion flagged for hepatotoxicity regardless of co-medications. Adding a second hepatically metabolized agent (modafinil) on top of this does not reduce that concern. Combining at this dose without physician awareness and periodic liver testing is not advisable.

What to watch for and when to seek care sooner than a scheduled visit

Report the following to a physician rather than waiting for a routine follow-up: yellowing of the skin or eyes, dark urine, right upper quadrant abdominal discomfort, or fatigue that feels qualitatively different from a baseline sleep disorder. These can be early signs of liver injury and warrant liver enzyme testing promptly. Separately, a resting heart rate persistently above 100 beats per minute, new or worsening headache, anxiety, or an inability to sleep despite wanting to can reflect excess combined stimulant load and should also prompt a call to the prescribing clinician, particularly if a cardiovascular risk factor is present.

Regulatory and label context

Modafinil (Provigil) is FDA-approved for narcolepsy, obstructive sleep apnea with residual sleepiness despite CPAP therapy, and shift-work sleep disorder [7]. The FDA label describes modafinil as a moderate CYP3A4 inducer and warns that CYP3A4-sensitive drugs (cyclosporine, certain oral contraceptives, some statins) may show reduced effect when co-administered [7]. The label does not address green tea extract or EGCG specifically; supplement-drug interactions are not typically studied in the trials that support drug approval, so their absence from a label reflects lack of formal study rather than a finding of safety.

Practical steps

Anyone taking modafinil who wants to add green tea extract should choose a decaffeinated, clearly labeled product, keep total daily EGCG below roughly 400 mg as a starting point for discussion, and disclose the supplement to the prescribing clinician rather than assuming it is inert because it is sold over the counter. Anyone already taking green tea extract who is newly prescribed modafinil should bring the product label to the prescribing visit so the exact EGCG and caffeine content can be documented, and should ask about baseline liver enzyme testing if the dose is in the moderate-to-high range described above. Supplement disclosure at prescribing visits is inconsistent in general medical care; surveys of prescription drug users have found that many people using supplements alongside prescription medication do not routinely mention it to their physician [14], which is part of why this combination is worth raising proactively rather than waiting to be asked.